3 mg [14C]-A4250 capsule ( DrugBank: - )

3 diseases

93. 原発性胆汁性胆管炎

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabo ...	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Pr ...	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom

臨床試験数 : 45 / 薬物数 : 21 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 5

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabo ...	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Pr ...	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom

臨床試験数 : 60 / 薬物数 : 26 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabo ...	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Pr ...	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom